Ranibizumab - 10mM histidine- histidine HCl buffer

CAS : 347396-82-1

Ref. 3D-BR171775

Informations sur le produit

• Nom: Ranibizumab - 10mM histidine- histidine HCl buffer
• Synonymes: Lucentis
• CAS: 347396-82-1

Description

Ranibizumab is a humanized monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and blocks its action. It is used in the treatment of age-related macular degeneration and other diseases characterized by neovascularization, such as diabetic retinopathy and retinopathy of prematurity. Intravitreal ranibizumab injections have been shown to be effective for neovascular age-related macular degeneration, with a reduction in choroidal neovascularization and visual acuity improvement demonstrated in clinical trials. This drug has also been shown to reduce the incidence of new lesions in the retina and choroid, as well as to reduce or delay the development of new vessels. Ranibizumab is administered by intravitreal injection, which means it is injected into the vitreous humor inside the eye. The medication can be given alone or with bevacizumab (another VEG

• Marque: Biosynth

Propriétés chimiques

• Degré de pureté: Min. 95 Area-%
• Couleur/Forme: Clear Liquid